Latest period
$999.00K
YoY change
+39.0%
5Y CAGR
-1.1%
Peak year (2022)
$7.69M
Cumulative CapEx
$15.78M
CapEx history chart for Tango Therapeutics (TNGX) from 2019 to 2025
Latest: $1.05M
CapEx growth chart for Tango Therapeutics (TNGX) from 2019 to 2025
Latest: +39.0%
CapEx history table for Tango Therapeutics (TNGX) from 2019 to 2025
| 2025 | $1.05M | +39.0% | +$294.00K | ||
| 2024 | $754.00K | -50.6% | −$772.00K | ||
| 2023 | $1.53M | -80.2% | −$6.17M | ||
| 2022 | $7.69M | +318.7% | +$5.86M | ||
| 2021 | $1.84M | +66.1% | +$731.00K | ||
| 2020 | $1.11M | -39.1% | −$711.00K | ||
| 2019 | $1.82M | — | — |
- 2025$1.05M+39.0%
- 2024$754.00K-50.6%
- 2023$1.53M-80.2%
- 2022$7.69M+318.7%
- 2021$1.84M+66.1%
- 2020$1.11M-39.1%
- 2019$1.82M—
CapEx values are taken from Tango Therapeutics's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About CapEx at Tango Therapeutics (TNGX)
According to Tango Therapeutics's latest reported financial statements, the company's current CapEx (TTM) is $999.00K. Capital expenditures (CapEx) are cash outlays for property, plant, and equipment and other long-lived productive assets — reported on the cash flow statement under investing activities. CapEx funds future capacity (factories, data centers, software, machinery), so rising spend can signal investment in growth, while heavy CapEx reduces free cash flow available to shareholders. We display CapEx as a positive amount (the absolute cash outflow); compare with revenue to gauge capital intensity and with total assets for the asset-base context.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
2025's annual CapEx for Tango Therapeutics (TNGX) came in at $1.05M – surged 39.0% year-over-year.
Through 2020–2025 (5 years), Tango Therapeutics CapEx delivered a -1.1% annualised rate; with a net decline across the window.
Tango Therapeutics CapEx plunged from $7.69M in 2022 to $1.05M in 2025, a 86.4% drawdown.
$7.69M stands as the all-time-high annual CapEx, posted in 2022, against a low of $754.00K during 2024.
Tango Therapeutics Capital Expenditures by Year
Tango Therapeutics Capital Expenditures 2025: $1.05M
Tango Therapeutics posted CapEx of $1.05M in 2025, surged 39.0% from 2024.
Tango Therapeutics Capital Expenditures 2024: $754.00K
In 2024, Tango Therapeutics reported CapEx of $754.00K, plunged 50.6% below 2023. This figure represents the lowest annual value in the available history.
Tango Therapeutics Capital Expenditures 2023: $1.53M
Tango Therapeutics CapEx in 2023 was $1.53M, plunged 80.2% below 2022.
Tango Therapeutics Capital Expenditures 2022: $7.69M
2022's CapEx for Tango Therapeutics came in at $7.69M, surged 318.7% from 2021. This figure represents the highest annual value in the available history.
Tango Therapeutics Capital Expenditures 2021: $1.84M
Tango Therapeutics CapEx in 2021 was $1.84M.
See more financial history for Tango Therapeutics (TNGX).
Sector peers by CapEx
Healthcare peers of Tango Therapeutics (TNGX), ranked by their latest CapEx
| $14.05B | |
| $7.84B | |
| $4.83B | |
| $4.11B | |
| $3.62B | |
| $2.81B | |
| $1.86B | |
| $1.21B |
- $14.05B
- $7.84B
- $4.83B
- $4.11B
- $3.62B
- $2.81B
- $1.86B
- $1.21B
Frequently asked questions
Tango Therapeutics (TNGX) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation